2022 annual financial data
XTL Biopharmaceuticals 2022 Revenue growth
Direct answer
Revenue growth was -131.31%.
Operating income was -880,000 USD and net income was -1,348,000 USD.
Operating cash flow was -901,000 USD.
Get free XTL Biopharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- -459,000 USD
- Operating income
- -880,000 USD
- Net income
- -1,348,000 USD
- Operating cash flow
- -901,000 USD